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The synthesis, characterization and biological activity of six bioorganometallic conjugates of 
ciprofloxacin with ferrocenyl, ruthenocenyl and cymantrenyl entities is described. Their antimicrobial 
activities were investigated against Gram-positive bacteria, Gram-negative bacteria and bloodstream 
forms of Trypanosoma brucei. Furthermore, morphological changes of bacterial cells upon treatment with 
the conjugates were examined by scanning electron microscopy. In addition, the cytotoxicity of the 
conjugates against tumor and normal mammalian cells was also investigated. The results showed that 
conjugation of an organometallic moiety can significantly enhance the antimicrobial activity of the 
antibiotic ciprofloxacin drug. It was found that N-alkyl cymantrenyl and ruthenocenyl ciprofloxacin 
conjugates were the most effective derivatives although other conjugates showed also significant 
antimicrobial activity. The increase in antimicrobial activity was most likely due to two independent 
mechanisms of action. The first mechanism is due to the bacterial topoisomerase inhibitory activity of 
ciprofloxacin while the second mechanism can be attributed to the generation of reactive oxygen species 
caused by the organometallic moiety. The presence of two modes of action enables the conjugates to kill 
bacteria in their stationary growth phase and to overcome drug resistance of S. aureus strains. In addition, 
the conjugates showed promising selectivity toward bacterial and parasite cells over mammalian cells.














































































Organometallic derivatization (or conjugation) of medicinally important molecules like drugs, drug leads 
or natural products has been shown to be an efficient method for obtaining new therapeutic and diagnostic 
agents.1-10 A major impetus into the research of organometallic compounds has been the development of 
anticancer agents. For instance, ferrocenyl derivatives of the anti-breast cancer drug tamoxifen are key 
examples of this group.11 Far less attention has been given towards the development of organometallic 
antibacterial and antiparasite drug derivatives. This field of research is, however, increasingly important 
due to the worldwide spread of drug-resistant bacteria and an urgent need for new antiparasite drugs.12-18 
Seminal report on ferrocenyl (Fc) derivatives of β-lactam antibiotics have been published in the 1970s.19 
Recently, our group reported on Fc and ruthenocenyl (Rc) derivatives of 6-aminopenicillinic acid (6-
APA) and 7-aminodesacetoxycephalosporanic acid (7-ADCA).20-23 Several atomic resolution X-ray 
crystal structures of the ruthenocenyl β-lactam derivatives complexed with bacterial CTX-M β-lactamase 
were solved providing structural insight into the mode of binding of the conjugates to the enzyme active 
site.21-23 Further, recent examples of organometallic derivatives of well-established antibacterial drugs or 
therapeutically promising antibiotics comprise ferrocenyl derivatives of novobiocin24 or ferrocenyl, 
cymantrenyl and half-sandwich chromium platensimicin derivatives.25,26 Other examples of 
organometallic antiparasite drug derivatives include antimalarial ferroquine,27,28 manganese(I) tricarbonyl 
complexes of ketoconazole, miconazole and clotrimazole,29 antimalarial ferrocenyl quinolones,30 
cymantrene and cyrhetrene chloroquines,31 antischistosomal Cr tricarbonyl praziquantel drug 
derivatives,32 and ferrocenyl derivatives of the anthelmintic drug monepantel.33
Quinolones are synthetic antibacterial drugs with broad-spectrum activity against Gram-positive and 
Gram-negative pathogenic strains. They are the only class of synthetic antibacterial drugs competing with 
β-lactam antibiotics in terms of effectiveness and worldwide clinical use. The story of quinolones started 
with the discovery of nalidixic acid in 1962.34 Since then, many generations of quinolones have been 
introduced into the market with norfloxacin,35 ofloxacin,36 ciprofloxacin,37 sitafloxacin,38 and 
nadifloxacin39 as relevant examples.
Quinolones cross the bacterial cell wall by passive diffusion, which is a major up-take mechanism in 
Gram-positive strains, and by porin-mediated influx mechanisms in Gram-negative strains.40 Quinolones 
are bacterial topoisomerases inhibitors.41 Topoisomerase inhibition has been, for a long time, considered 













































































as a sole mechanism of quinolones bactericidal activity. However, recent reports showed that this 
mechanism is accompanied by the ability of quinolones to generate reactive oxygen species (ROS) in 
bacterial cells.42,43 Bacterial DNA gyrase and DNA topoisomerase IV belong to the type II DNA 
topoisomerase family  and they are validated targets for quinolone antibacterial therapy.41,44 Both of these 
enzymes change bacterial chromosome topology by transient double-strand DNA scission, a change of 
the DNA linking number, and subsequent covalent linking of the cleaved strands.45,46 All topoisomerases 
can relax supercoiled DNA, but only DNA gyrase can also introduce negative supercoils in a reaction that 
require the hydrolysis of ATP.47 Bacterial topoisomerases II consist of A and B subunits which must 
aggregate to form an A2B2 active tetramer complex. XRD molecular structures of gyrase-
fluoroquinolones adducts have been reported,48,49 indicating that quinolones do not bind to either DNA or 
topoisomerase enzyme alone. Instead, they bind to the DNA-A2B2 complex targeting the DNA-cleavage 
active site positioned at the DNA gate of the enzyme. This mode of binding hinders effective DNA 
religation and results in lethal DNA double-strands breaks.50 The clinical success of quinolones came 
with the price of the emergence of bacterial resistance to this class of drugs.51 To address this problem, 
there is a need of quinolones with activity against drug-resistant clinical isolates of pathogenic bacterial 
strains.  
Here we describe the preparation of six organometallic ciprofloxacin (CIP) derivatives bearing either 
ferrocenyl (1,4), ruthenocenyl (2,5) or cymantrenyl (3,6) moieties and the biological activities of these 
compounds. The compounds were tested for their activity against a panel of Gram-positive and Gram-
negative laboratory and clinical bacterial strains. There is evidence that common different classes of 
antibiotics (e.g., fluoroquinolones and β-lactams) act as ROS generating agents52 and that the oxidative 
stress (OS) triggered by these antibiotics contributes to their antibacterial activity43 and toxicity.52 
Because of this we also investigated the organometallic ciprofloxacin derivatives for their ability to 
generate ROS in bacteria and attempted to correlate the ROS production with the antibacterial activity of 
the compounds. In addition, we report on inhibitory activity studies of 1-6 towards bacterial gyrase and 
topoisomerase IV. We also evaluated the antitrypanosomal activity of 1-6 against the protozoan parasite 
Trypanosoma brucei. Furthermore, the effect of compounds 4, 5 and 6, as well as ciprofloxacin (CIP), on 
the morphology of E. coli and S. aureus was studied by scanning electron microscopy (SEM).
Results and discussion
Synthesis













































































Two groups of organometallic ciprofloxacin (CIP) derivatives were obtained as depicted in 
Scheme 1. In both groups the organometallic-spacer moiety substitutes the hydrogen atom 
of the piperazin-1-yl ring in CIP. Compounds 1-3 are N-acyl and 4-6 are N-alkyl derivatives, 
respectively. Derivatives 1-3 were obtained in reaction of CIP with the appropriate carboxylic 
acid A, B or C in dichloromethane in the presence of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC-HCl) and 4-(dimethylamino)pyridine 
(DMAP) (Scheme 1). Compounds 4-6 were obtained by a one-pot, two-step process 
developed in our group consisting of dehydrohalogenation of compounds D-F followed by a 
Michael addition reaction of in situ generated acryloyl-intermediates with ciprofloxacin.53 
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Scheme 1 Synthesis of organometallic ciprofloxacin conjugates 1-6
Ciprofloxacin derivatives 1-6 were isolated as crystalline solids in 80, 51, 52, 80, 87, and 85% yields, 
respectively. All compounds were characterized by 1H, 13C-NMR, IR spectroscopy, mass spectrometry 
and elemental analyses. The 1H NMR spectra of 1-6 are shown in Figs. S1-S6 (ESI). The obtained 
analytical data confirmed the proposed structures. In addition, the structure of 4 and 6 in solid state was 
determined by single-crystal X-ray structural analysis.
X-ray structure determination
Crystals of 4 and 6 suitable for single-crystal X-ray diffraction structure determination were obtained by 
slow diffusion of n-pentane into a 1,2-dimethoxyethane solution of 4 and into a chloroform solution of 6, 
respectively. The crystal and structure refinement data are presented in Table S1. The molecular structure 
of 4 and 6 are shown in Figure 1 and 2, together with selected geometrical parameters. Full list of bond 
distances (Å), valence and torsion angles (o) are listed in Tables S2-S7.













































































Fig. 1 Molecular diagram of 4 with atomic displacement ellipsoids at the 25% probability level; Mp1 and 
Mp2 correspond to mid-points of the substituted and unsubstituted cyclopentadienyl rings, respectively. 
Selected bond lengths [Å] and angles [o]: Mp1−Fe, 1.659(4); Mp2−Fe, 1.632(2); Fe39−C29, 2.033(7); 
Fe39−C30, 2.063(8); Fe39−C36, 2.030(7); C29−C27, 1.466(9); C26−C25, 1.514(8); C30−C29, 1.430(9); 
O28−C27, 1.229(7); O21−C20, 1.339(7); O22−C20, 1.209(7); N14−C25, 1.471(7); N1−C17, 1.456(6); 
F24−C6, 1.361(6); C32−C33−C29, 106.8(6); O28−C27−C26, 121.3(6); N14−C25−C26, 121.3(6); 
N14−C25−C26, 114.2(5); C30−C29−C33−C32, 0.6(9); C26−C27−C29−C30, 170.3(7).
Fig. 2 Molecular diagram of 6 with atomic displacement ellipsoids at the 25% probability level; Mp1 
corresponds to mid-point of the cyclopentadienyl ring. Selected bond lengths [Å] and angles [o]: 
Mp1−Mn40, 1.759(3); Mn40−C29, 2.118(5); Mn40−C36, 1.793(5); C29−C27, 1.498(7); C26−C25, 
1.526(6); C30−C29, 1.403(8); O28−C27, 1.198(8); O21−C20, 1.319(5); O22−C20, 1.212(5); N14−C25, 
1.470(6); N1−C17, 1.492(8); F24−C6, 1.365(4); C32−C33−C29, 107.2(6); O28−C27−C26, 122.0(5); 
N14−C25−C26, 113.2(5); C30−C29−C33−C32, 0.2(8); C26−C27−C29−C30, -0.4(9).
Compound 4 and 6 both crystalized in the monoclinic space group, ferrocene derivative 4 in the C2/c and 
cymantrene derivative 6 in the P21/c. The single-crystal X-ray structure analysis confirmed postulated 
structures in which the organometallic moiety was bound to the nitrogen atom of the piperazin-1-yl 
group. The iron atom in 4 was symmetrically located between the cyclopentadienyl (Cp) rings with a 













































































distance of 1.659(4) Å and 1.631(2) Å to the midpoints of each cyclopentadienyl ring (Mp1 and Mp2, 
respectively). The ferrocenyl moiety in 4 deviated from the staggered conformation by about -10o. The 
manganese atom in 6 was bonded to the Cp ligand and to the three carbonyl ligands. This is the typical 
molecular architecture of cymantrenyl three-legged piano-stool derivatives.54 In the crystal lattice, 
individual molecules of either, 4 or 6 were involved in intramolecular C−H···O and C−H···F hydrogen 
bonds and in the network of weak π- π and C−F···π contacts (Fig. S7 and S8, Table S8-S13). Of notice is 
that the crystal lattice of 6 contained solvent accessible voids running along the crystallographic b-
direction (Fig. S8, voids are marked in yellow).
Antibacterial activity
The antibacterial activity of compounds 1-6 and their commercially available metallocene precursors 
(ferrocene carboxylic acid A, ruthenocene carboxylic acid B, and cymantrene carboxylic acid C) was 
tested against a set of reference Gram-negative strains (Escherichia coli ATCC 25922, E. coli NCTC 
8196, Proteus vulgaris ATCC 49990, Klebsiella pneumoniae ATCC 13883) and Gram-positive strains 
(Staphylococcus aureus ATCC 6538, S. aureus ATCC 29213, Staphylococcus epidermidis ATCC 
12228), and additionally against two clinical bone isolates of methicillin-resistant S. aureus (MRSA) as 
well as against S. aureus ATCC 6538 CIPR, a mutant strain resistant to high concentrations of CIP (>60 x 
MIC) that was obtained in our laboratory through selection using increasing concentrations of the 
antibiotic on agar plates. All three tested metallocene precursors did not have any antibacterial activity 
within the tested concentrations of 0.2 – 200 μM (data not shown). The antibacterial activity of 1-6 are 
shown in Table 1 as minimal inhibitory concentration (MIC) values. In general, compounds 4-6 showed 
higher antibacterial activity against all strains tested compared to their congeners 1-3. Noticeably, 
compounds 5 and 6 were more active against E. coli ATCC 25922 strain than CIP. Their MIC values 
were 0.0006 and 0.0001 µM, respectively, while the MIC of CIP was 0.01 µM. It means that in the case 
of 6, the MIC value was 100 times lower than that of CIP. Furthermore, compound 6 was more active 
than CIP against S. aureus ATCC 6538 and K. pneumoniae ATCC 13883 with MICs of 0.4 and 0.001 
µM, respectively. In the former case, the MIC value of 6 was 50 times lower than that of CIP. 
Compounds 5 and 6 were also highly active against all Gram-positive strains with similar MIC values as 
CIP. The most active compounds of 1-3 series was the cymantrenyl derivative 3. It showed better 
antibacterial activity against both D15 and D17 MRSA strains than CIP with MIC values of 0.8 µM, and 
thus was 4 times more active than CIP. It should be noted that both  clinical isolates showed  reduced 
susceptibility to CIP. Interestingly, the same four-fold increase in potency of compound 3 over CIP was 
also observed for the CIP resistant S. aureus 6538 CIPR strain, despite the fact that the MIC values of 
both drugs were greater than those for the wild type strain. As antibacterial drugs can be either 
bacteriostatic (inhibition of growth) or bactericidal (killing of bacteria), we determined also a minimal 













































































bactericidal concentration (MBC) for compounds 1-6 (Table 1). The MBC values for the most active 
compounds 5 and 6 against E. coli ATCC 25922, and 6 against K. pneumoniae were approximately 10 
times and 5 times lower, respectively, than those obtained for CIP against these strains. However, the 
MBC/MIC ratio was > 4, which indicates more bacteriostatic rather than bactericidal activity.55 In the 
case of the other strains where the MIC values of these compounds were similar to that of CIP, the 
compounds showed predominantly bactericidal activity (MBC/MIC ratio < 4, Table 1). Predominant 
bactericidal mode of activity was also observed for all other compounds. 
Table 1 Minimal inhibitory concentration (MIC in μM) and minimal bactericidal concentration (MBC, in 
μM) of 1-6 and CIP against panel of Gram-negative and Gram-positive bacterial strains. CIPR-resistant to 
high concentration of CIP
na – no activity, nd – not determined
The influence of N-acetyl-L-cysteine (NAC) on antibacterial activity
There is a growing evidence that some antibiotics, in addition to their individual activity against a specific 
target, have also the ability to produce reactive oxygen species (ROS). The mechanism of ROS 
production involves the activation of the tricarboxylic acid (TCA) cycle followed by hyper-induction of 
the electron transport chain.43, 56-58 In order to assess whether ROS production played a role in the 
antibacterial activity of our organometallic ciprofloxacin derivatives, we studied the antibacterial 
Antibacterial activity [μM]strain
1 2 3 4 5 6 CIP
MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC
E.coli
ATCC 25922 6.2 >25 6.2 >25 6.2 25 0.08 0.08 0.0006 0.005 0.0001 0.005 0.01 0.04
E.coli 
NCTC 8196 25 >25 25 >25 12.5 25 0.4 0.4 0.04 0.08 0.04 0.04 0.04 0.08
P.vulgaris 
ATCC 49990 na nd na nd na nd 1.6 1.6 3.1 6.2 0.2 0.2 0.1 0.2
K.pneumoniae
ATCC 13883 na nd na nd 25 >25 0.2 0.4 0.05 0.2 0.001 0.01 0.05 0.05
S.aureus 
ATCC 6538 6.2 25 6.2 25 0.8 3.1 3.1 6.2 0.8 1.6 0.4 3.1 0.8 1.6
S.aureus 
ATCC 29213 6.2 12.5 6.2 25 0.8 1.6 3.1 6.2 1.6 1.6 0.8 1.6 0.4 1.6
S.epidermidis 
ATCC 12228 12.5 12.5 12.5 >25 1.6 1.6 1.6 3.1 0.8 1.6 0.8 0.8 0.4 0.8
S.aureus D15 
(MRSA) 6.2 12.5 6.2 12.5 0.8 1.6 6.2 6.2 3.1 6.2 3.1 6.2 3.1 3.1
S.aureus D17 
(MRSA) 6.2 25 6.2 >25 0.8 3.1 6.2 12.5 3.1 6.2 3.1 12.5 3.1 6.2
S. aureus CIPR nd nd nd nd 12.5 50 50 >50 50 >50 50 >50 50 >50













































































activity of the three most active compounds 3, 5, and 6 in the presence of the free radical scavenger N-
acetyl-L-cysteine (NAC) against E. coli ATCC 25922 and S. aureus ATCC 6538 strains (Table 2).
Table 2 Antibacterial activity of 3, 5, 6 and CIP in the presence of 10 mM N-acetyl-l-cysteine (NAC) 
antioxidant after 24 h treatment expressed as MICNAC [μM] and [MICNAC]/MIC ratio where [MICNAC] is a 
value of MIC determined in the presence of the antioxidant
In the case of the E. coli strain, a significant increase in the MIC value was observed for compounds 5 
and 6 and for CIP in the presence of NAC (Table 2). The [MICNAC]/MIC ratio for 5 and 6 was greater 
than 1000 while that for CIP was only 16. For compound 3, which had a much higher MIC value against 
E. coli ATCC 25922, the effect of NAC was negligible.  For the S. aureus strain, a similar increase in the 
MIC value was observed for all three compounds and CIP. However, the effect was less pronounced and 
the [MICNAC]/MIC ratio was only moderate (Table 2). Nevertheless, these results indicate that ROS seem 
to play a role in the mode of antibacterial action of compounds 3, 5, and 6.
Antibacterial activity in stationary phase
Most bactericidal antibiotics require bacteria to be actively dividing in order to exhibit their killing 
activity. However, in many infections, depending on their stage, bacteria divide very slowly if at all 
(stationary phase) and form biofilms. Moreover, some cells in these biofilms are so called peristers, which 
have a significantly reduced metabolism and tend to have acquired temporary antibiotic-resistant 
phenotypes.59, 60, 61 Therefore, compounds with the ability to kill bacteria in their stationary growth phase 
are especially sought-after. For this reason, we studied the antibacterial activity of compounds 4, 5, and 6 
against E. coli ATCC 25922, and 3, and 6 against S. aureus ATCC 6538 in their stationary growth phase.
 
MICNAC [µM] [MICNAC]/MIC [ratio]
3 5 6 CIP 3 5 6 CIP
E.coli ATCC 25922 6.2 0.6 0.3 0.16 1 1000 3000 16
S. aureus ATCC 6538 6.2 6.2 6.2 6.2 7.75 7.75 15.5 7.75













































































Fig. 3 Bactericidal effect of organometallic ciprofloxacin derivatives observed after 24 h exposure of 
stationary-phase E. coli and S. aureus cells. Compounds 4, 5, 6, and CIP were tested at 0.1 μM against E. 
coli and compounds 3, 6, and CIP at 2 μM against S. aureus. Prior to treatment with the compounds, 
cultures were grown for 24 h to generate high cell density stationary-phase batches. The results were 
expressed as means ± SEM from three independent experiments (n = 3). Comparisons between 
compounds and untreated control (C) were made using One-way ANOVA analysis of variance (* P<0.05, 
*** P<0.001).
All three organometallic ciprofloxacin derivatives 4, 5, and 6 resulted in a statistically significant 
decrease in the viability of stationary-phase E. coli cells compared to the untreated control (Fig. 3). The 
highest bactericidal activity showed compound 6, resulting in a decrease in cell viability from 3.3 x 108 to 
2.2 x 106 CFU/mL, followed by compound 5 and 4, which perfectly coincided with the MICs pattern for 
exponentially growing bacteria. CIP also caused a statistically significant decrease in bacterial viability, 
however, it was about 10 times less potent than the organometallic ciprofloxacin derivatives  (decrease 
from 3.3 x 108 to 1.6 x 107 CFU /mL). 
Bactericidal activity on stationary-phase S. aureus cells was evaluated with compounds 3 and 6, which 
had the lowest MIC values against exponentially growing staphylococci (see above). Both compounds 
caused a statistically significant decrease in the viability of the bacteria compared to the untreated control 
(from 2.4 x 109 to 3.4 x 108  CFU/mL for 3, and 6.3 x 108 CFU/mL for 6). In contrast, CIP did not show 
bactericidal activity at the tested concentration against S. aureus in the stationary growth phase. 
As fluoroquinolones such as CIP require cell activity (replication, transcription) to establish their 
bactericidal activity,51, 62 it can be hypothesized that our new organometallic ciprofloxacin derivatives 
seem to have, in addition to their ability to inhibit topoisomerase activity (see below), another mode of 
action. This other mechanism seems to be responsible for the killing of non-dividing bacteria. Based on 
the results obtained with NAC, it can be speculated that this second mode of action is due to ROS and 













































































oxidative stress generation in bacterial cells. The bactericidal activity against stationary-phase bacteria of 
organometallic ciprofloxacin derivatives may be useful in the treatment of chronic infectious involving 
slow-growing or biofilm-forming pathogens.
Topoisomerase inhibitory activity
As mentioned above, quinolones including CIP exhibit their major mode of action by suppressing 
bacterial type IIA topoisomerases, i.e. DNA gyrase and topoisomerase IV.51, 63 All organometallic 
ciprofloxacin derivatives except 1 inhibited the introduction of supercoils by E. coli gyrase and the 
decatenation process by S. aureus topoisomerase IV at a concentration of 50 μM (Fig. S9). For 
compounds 3 and 6, detailed densitometric analyses were performed and the IC50 values (concentrations 
of compounds that inhibit the activity of an enzyme by 50%) were determined (Table 3). 
Table 3 IC50 values of 3, 6 and CIP for inhibition of E. coli DNA gyrase and S. aureus topoisomerase IV
The topoisomerases inhibitory activity of both compounds was weaker than that of CIP. Compound 6 
showed higher inhibitory activity against DNA gyrase (IC50 = 2.54 µM) than against topoisomerase IV 
while compound 3 showed a reverse inhibition pattern. It is well established that among Gram-negative 
bacteria the primary molecular target for CIP is DNA gyrase. In the case of Gram-positive bacteria, 
topoisomerase IV is the primary molecular target and DNA gyrase plays only a secondary role.64, 65 In 
line with this fact, 6 was the most active compound against E. coli bacteria and its inhibitory activity of E. 
coli DNA gyrase was much higher than that of topoisomerase IV. On the other hand, the antibacterial 
activity of 3 was mainly directed against staphylococci and its ability to inhibit S. aureus topoisomerase 
IV was stronger than that for DNA gyrase (Table 3, Figure 4).
IC50 [µM]
3 6 CIP[64]
DNA Gyrase 13.37 2.54 0.15
Topoisomerase IV 6.43    16.85 4.00 













































































Fig. 4 Inhibition assay for E. coli DNA gyrase in the presence of compound 6 (A) and S. aureus 
topoisomerase IV in the presence of compound 3 (B). [A: 1 - relaxed pBR – negative control; 2 – E. coli 
DNA gyrase – positive control; 3-5 - compound 6 at concentrations of 5, 10, and 50 μM; B: 1 – 
kinetoplast catenated DNA – negative control; 2 – S. aureus topoisomerase IV – positive control; 3-5 – 
compound 3 at concentration of 5, 10, and 20 μM].
Scanning Electron Microscopy (SEM)
Due to its antibacterial mode of action by inhibiting topoisomerases, CIP is known to indirectly affect the 
expression of many macromolecules within bacterial cell. These changes may manifest in several ways, 
including disturbances in the production of cell wall components followed by changes in cell shape and 
size.66 To determine any structural changes in bacterial morphology upon expose to organometallic 
ciprofloxacin derivatives, scanning electron microscopic images of the reference E. coli and S. aureus 
strains were taken after 12 h treatment with the most promising compounds 4-6 and CIP (as control) at 
their MICs. The micrographs showed the smooth morphology of cell surface in non-treated control 
samples (Fig. 5A and 5F), while the treated cells of both microorganisms displayed roughness or damage 
to the cell wall or outer membrane. In addition, elongation of E. coli cells (Fig. 5B-D) and changes in size 
and volume of S. aureus cells (Fig. 5G-I) were also noticed.













































































Fig. 5 SEM analysis of bacterial cell morphology after 12 h treatment with derivatives 4-6 and CIP. Top 
panels, E. coli cells; bottom panels, S. aureus cells. (A and F) control, non-treated samples; bacteria 
treated with compounds 4 (B and G), 5 (C and H), 6 (D and I), and CIP (E and J). Scale bars: 500 nm in 
F, G, I, and J; 1 µm in A-D and H; 3 µm in E.
Antitrypanosomal activity
The trypanocidal and cytotoxic activity of organometallic ciprofloxacin conjugates 1-6 was evaluated 
with bloodstream forms of Trypanosoma brucei and human acute promyelocytic leukemia HL-60 cells, 
respectively. Whereas the N-acyl conjugated derivatives 1-3 displayed no toxicity towards trypanosomes, 
the N-alkyl conjugated compounds 4-6 showed trypanocidal activity with MIC values of 10 μM and GI50 
values of around 3 μM (Table 4). 
Table 4 MIC (μM) and GI50 (μM) values of compounds 1-6 and CIP for T. brucei bloodstream forms and 
human HL-60 cells
a MIC (minimum inhibitory concentration, i.e., the concentration of the compound at which all cells were killed); b 
GI50 (50% growth inhibition, i.e., the concentration of a compound necessary to reduce the growth rate of cells by 
50% to that of controls)
Thus, the toxicity pattern of the compounds against trypanosomes reflects that of the derivatives against 
bacteria (see above). Encouragingly, compounds 4-6 exhibited more than 10 times less cytotoxicity 
towards HL-60 cells resulting in moderate selectivity indices (Table 4). In addition, compounds 4-6 were 
T. brucei HL-60 Selectivity
Compound MICa(μM) GI50b(μM) MIC (μM) GI50 (μM) MIC ratio GI50 ratio
1 >100 >100 >100 >100 1 1
2 >100 >100 >100 >100 1 1
3 100 29.2±5.6 >100 >100 >1 >3.4
4 10 3.32±0.32 100 49.3±3.7 10 14.8
5 10 2.83±0.10 100 36.9±0.6 10 13.0
6 10 2.58±0.37 100 35.5±1.8 10 13.8
3 100 29.2±5.6 >100 >100 >1 >3.4
Pp-Cym >100 62.3±24.7 >100 >100 1 >1.6
CIP 100 30.9±3.3 >100 >100 >1 >3.2
Pp-Cym + CIP 100 30.2±1.8 n.d. n.d. n.d. n.d.
Suramin 0.1-1 0.057±0.005 >100 >100 >100-1000 >1754













































































about 10 times more trypanocidal than unconjugated CIP. In order to see whether the trypanocidal 
activity of the derivatives 4-6 was due to the organometallic component or to a synergistic effect of the 
organometallic part in combination with CIP, we investigated the antitrypanosomal activity of propionyl 
cymantrene (Pp-Cym; Fig. S10) alone and together with CIP (Table 4). Pp-Cym on its own displayed 
almost no trypanocidal activity. The combination of Pp-Cym and CIP exhibited the same trypanocidal 
activity as CIP alone, indicating that there was no synergy between the two compounds. This means that 
the increased antitrypanosomal activity of derivative 6 was due to the covalent linkage of Pp-Cym to 
CIP. For comparison, the trypanocidal activity of suramin, one of the commercial drugs to treat humans 
infected with T. brucei, was also determined. The MIC and GI50 values of suramin were 10-100 and 45-
58 times lower, respectively, than those of compounds 4-6 (Table 4). As suramin is nontoxic to human 
HL-60 cells, its selectivity indices were substantially larger. Nevertheless, organometallic N-alkyl CIP 
derivatives provide interesting templates for rational antitrypanosomal drug development.
Cytotoxicity
Cytotoxic activity of compounds 1-6 was investigated in vitro on non-tumorigenic mouse murine 
fibroblast L929 and human cervical epithelioid carcinoma HeLa cells using the tetrazolium (MTT) assay. 
Obtained GI50 values are shown in Table 5. 
Table 5 Effect of 1-6 and CIP on the viability of L929 and HeLa cells after 24 h treatment. The results 
were expressed as GI50 ± SEM from three independent experiments (n = 3)
nd – not determined
All CIP conjugates, including the three most active derivatives against bacteria (3, 5, and 6) were also 
found to be toxic for cell lines. Human HeLa cells were more sensitive to the compounds than murine 
fibroblasts. All derivatives decreased cell viability more than CIP. However, the GI50 values were 
significantly higher than the corresponding MIC values. To visualize this, GI50/MIC ratios were 
calculated as a parameter demonstrating the selectivity of 1-6 towards bacterial cells (Table 6). 
GI50 [μM]
1 2 3 4 5 6 CIP
L929 61±2.7 33±1.0 85±2.2 111±5.4 58±4.9 87±8.7 >1000±nd
HeLa 63±3.1 71±4.6 27±1.3 97±10.7 36±3.5 58±4.6 560±22.6













































































Table 6 Selectivity of compound 1-6 towards bacterial cells expressed as GI50/MIC ratios where GI50, the 
concentration that inhibited mammalian cells viability by 50%, is divided by the bacterial MIC value
Thus, a larger ratio (i.e. bigger difference between GI50 and MIC values) for a particular compound means 
a lesser risk of its toxic side-effects when used as an antibacterial agent. The effective antibacterial 
concentrations of compounds 5 and 6 were found to be more than 103 – 105 times lower than their toxic 
concentrations for L929 and HeLa cells. 
GI50/MIC [Range]
1 2 3 4 5 6
L929 2-10 1-3 3-11x101 18-14x102 19-96x103 93-29x105
HeLa 3-10 3-6 1-34 16-12x101 12-60x103 19-58x105














































































This study has shown that the linkage of the antibiotic ciprofloxacin with organometallic 
moieties yielded conjugates with potent antimicrobial activity. Several conjugates displayed 
increased bactericidal and bacteriostatic activity against Gram-negative and Gram-positive 
bacteria as well as against MRSA strains. In addition, some derivatives showed improved 
antitrypanosomal activity when compared to their unconjugated starting compounds. The 
most potent derivatives were N-alkyl cymantrenyl and ruthenocenyl conjugates of 
ciprofloxacin. The observed increased antimicrobial activity of the conjugates was most likely 
due to two mechanisms of action; inhibition of DNA gyrase and topoisomerase IV by 
ciprofloxacin moiety and ROS production by the organometallic moiety. In conclusion, this 
study has demonstrated that the conjugation of organometallics to antimicrobial drugs is a 
promising approach in the search for new antibiotics. In addition, antimicrobial agents with 
dual or multiple modes of action may be a promising strategy in combating drug resistance.
Experimental
General methods 
All preparations were carried out using standard Schlenk techniques. Chromatographic 
separations used silica gel 60 (Merck, 230-400 mesh ASTM). DMF was distilled and purged 
with argon prior to use. Other solvents were of reagent grade and used without prior 
purification. Ciprofloxacin and carboxylic acids A-C were purchased from commercial 
supplier and used without further purification. Compounds D-F were obtained according to 
literature.53,54 1H NMR (600 MHz) and 13C{H} NMR (150 MHz) spectra were recorded on a 
Bruker Avance III 600 spectrometer operating at 298 K. Chemical shifts are reported in  
units (ppm) using the residual signal of DMSO (1H  2.50 ppm, 13C  39.70) as reference. EI 
mass spectra were recorded on a Finnigan MAT 95 mass spectrometer. Electrospray mass 
spectra were obtained on a ThermoFisher Exactive Plus instrument with an Orbitrap mass 
analyser in positive ion mode at a resolution of R = 70.000 and a solvent flow rate of 10 μL 
min–1 using acetonitrile as solvent. For protein interaction study, water was used as solvent 
and the flow rate was increased to 100 µL min-1. Only the most prominent peak of each 
isotope pattern is reported. IR spectra (KBr pellets) were measured on a FTIR Nexus Nicolet 
apparatus. Microanalyses were carried out by the Analytical Services of the Polish Academy 
of the Sciences (Łódź).  
Synthesis













































































General procedure for the synthesis of compounds 1-3
Ciprofloxacin A (116 mg, 0.35 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
hydrochloride (75 mg, 0.39 mmol) and 4-(dimethylamino)pyridine (4.3 mg, 0.04 mmol) were 
subsequently added to a stirred solution of either ferrocene carboxylic acid A (81 mg, 0.35 
mmol), ruthenocene carboxylic acid B (96 mg, 0.35 mmol), or cymantrene carboxylic acid C 
(87 mg, 0.35 mmol) in dichloromethane (20 mL) at 0 oC. The reaction mixture was stirred at 
ambient temperature for 24 h. Then, the reaction mixture was poured onto water, washed once 
with 5 mL of 5% HClaq and extracted with dichloromethane. The organic layer was separated, 
dried over anhydrous MgSO4, filtered and all volatiles were evaporated under reduced 
pressure. The remaining material was subjected to column chromatography on silica gel with 
dichloromethane/methanol (50:1 v/v) as eluent. Crystallization from a dichloromethane/n-
hexane mixture gave analytically pure samples. Compound 1 was obtained as a yellow solid 
(153 mg, 80% yield), 2 as a colorless solid (105 mg, 51% yield) and 3 as a beige solid (102 
mg, 52% yield), respectively.
1: 1H NMR (600 MHz, DMSO-d6):  = 15.19 (s, 1H, COOH), 8.67 (s, 1H, =C-H), 7.94 (d, 
JHF = 12.6 Hz, 1H, Harom), 7.61 (bs, 1H, Harom), 4.62 (s, 2H, α-C5H4), 4.42 (s, 2H, β-C5H4), 
4.28 (s, 5H, C5H5), 3.92 (bs, 4H, C4H8N2), 3.82 (s, 1H, CH cyclopropyl), 3.41 (s, 4H, 
C4H8N2), 1.33 (s, 2H, CH2 cyclopropyl), 1.19 (s, 2H, CH2 cyclopropyl). EI-MS: m/z = 566 
[M+Na]+, 544 [M+H]+. FTIR (KBr ν [cm-1]): 3431 (COOH), 3110, 3082, 3055, 2862, 1743 
(C=O), 1614 (C=O), 1509, 1493, 1468, 1455, 1256, 1029, 1009, 828. Anal. Calcd for 
C28H26N3O4FFe (%): C 61.89, H 4.82, N 7.73; Found: C 61.74, H 4.78, N 7.75.
2: 1H NMR (600 MHz, DMSO-d6):  = 15.19 (s, 1H, COOH), 8.67 (s, 1H, =C-H), 7.94 (d, 
JHF = 13.2 Hz, 1H, Harom), 7.60 (d, JHF = 7.2 Hz, 1H, Harom), 4.92 (pt, JHH = 1.8 Hz,  2H, α-
C5H4), 4.75 (s, JHH = 1.8 Hz, 2H, β-C5H4), 4.70 (s, 5H, C5H5), 3.89 (bs, 4H, C4H8N2), 3.82 (s, 
1H, CH cyclopropyl), 3.36 (s, 4H, C4H8N2), 1.33 (m, 2H, CH2 cyclopropyl), 1.19 (m, 2H, 
CH2 cyclopropyl). EI-MS: m/z = 590 [M+H]+. FTIR (KBr ν [cm-1]): 3399 (COOH), 3111, 
3058, 2960, 2886, 2859, 1743 (C=O), 1616 (C=O), 1510, 1498, 1467, 1441, 1254, 1025, 
1008, 822. Anal. Calcd for C28H26N3O4FRu (%): C 57.14, H 4.45, N 7.14; Found: C 57.23, H 
4.38, N 6.89.
3: 1H NMR (600 MHz, DMSO-d6):  = 15.16 (s, 1H, COOH), 8.67 (s, 1H, =C-H), 7.94 (d, 
JHF = 12.6 Hz, 1H, Harom), 7.58 (bs, 1H, Harom), 5.58 (s, 2H, α-C5H4), 5.09 (s, 2H, β- C5H4), 
3.79 (bs, 5H, C4H8N2 + CH cyclopropyl), 3.38 (bs, 4H, C4H8N2), 1.32 (s, 2H, CH2 
cyclopropyl), 1.18 (s, 2H, CH2 cyclopropyl). 13C{1H} NMR (150 MHz, DMF-d7):  = 225.1, 













































































177.3, 166.5, 163.6, 156.9 (d,1JCF = 249.0 Hz), 148.5, 145.6 (d, 2JCF = 10.3 Hz), 139.9, 119.8, 
111.4 (d, 2JCF = 23.1 Hz), 107.6, 107.2, 97.0, 87.9, 83.0, 50.1, 47.0, 36.3, 7.9. ES-MS: m/z = 
562 [M+H]+. FTIR (KBr ν [cm-1]): 3055, 2913, 2865, 2022 (Mn-CO), 1970 (Mn-CO), 1917 
(Mn-CO), 1724 (C=O), 1627 (C=O), 1506, 1472, 1455, 1422, 1256, 1182, 1011. Anal. Calcd 
for C26H21N3O7FMn (%): C 55.63, H 3.77, N 7.48; Found: C 55.59, H 3.77, N 7.44.
General procedure for the synthesis of compounds 4-6
Triethylamine (97 µL, 0.7 mmol) was added to a stirred solution of either (3-
chloropropionyl)-ferrocene D (97 mg, 0.35 mmol), (3-chloropropionyl)-ruthenocene E (113 
mg, 0.35 mmol), or (3-chloropropionyl)-cymantrene F (103 mg, 0.35 mmol) in N,N-
dimethylformamide (15 mL) at ambient temperature. After 20 min of stirring, ciprofloxacin 
(116 mg, 0.35 mmol) was added, and the reaction mixture was stirred at a temperature of 
either 85 oC for 5 h in case of D and E or 75 oC for 4 h in case of F. Subsequently, all 
volatiles were evaporated under reduced pressure and the residue was dissolved in 
dichloromethane (~10 mL), washed with 5 mL of 5% HClaq and extracted with 
dichloromethane. The organic layer was dried over MgSO4, filtered and evaporated to 
dryness. The residue was subjected to column chromatography on silica gel with 
dichloromethane/methanol (50:1 v/v) as eluent. Crystallization from a dichloromethane/n-
hexane mixture gave analytically pure samples. Compound 4 was obtained as an orange solid 
(160 mg, 80% yield), 5 as a yellow solid (188 mg, 87% yield) and 6 as a pale orange solid 
(175 mg, 85% yield).
4: 1H NMR (600 MHz, DMSO-d6):  = 15.20 (s, 1H, COOH), 8.65 (s, 1H, =C-H), 7.90 (d, 
JHF = 12.6 Hz, 1H, Harom), 7.56 (bs, 1H, Harom), 4.84 (s, 2H, α-C5H4), 4.58 (s, 2H, β-C5H4), 
4.27 (s, 5H, C5H5), 3.83 (s, 1H, CH cyclopropyl), 3.34 (s, 4H, C4H8N2), 2.95 (bs, 2H, CH2), 
2.76 (bs, 2H, CH2), 2.68 (s, 4H, C4H8N2), 1.30 (s, 2H, CH2 cyclopropyl), 1.18 (s, 2H, CH2 
cyclopropyl). 13C{1H} NMR (150 MHz, DMSO-d6):  =202.4, 176.4, 166.0, 164.0, 153.1 
(d,1JCF = 249.9 Hz), 148.1, 145.3 (d, 2JCF = 10.3 Hz), 139.3, 118.6, 111.0 (d, 2JCF = 23.1 Hz), 
106.8, 106.4, 79.3, 72.3, 69.7, 69.3, 52.9, 52.6, 49.6, 36.6, 7.7. EI-MS: m/z = 572 [M+H]+. 
FTIR (KBr ν [cm-1]): 3420 (COOH), 3088, 2952, 2930, 2875, 1724 (C=O), 1663 (C=O), 1628 
(C=O), 1612 (C=O), 1506, 1494, 1458, 1380, 1338, 1260. Anal. Calcd for C30H30N3O4FFe 
(%): C 63.06, H 5.29, N 7.35; Found: C 63.06, H 5.56, N 7.28.
5: 1H NMR (600 MHz, DMSO-d6):  = 15.20 (s, 1H, COOH), 8.66 (s, 1H, = C-H), 7.90 (d, 
JHF = 13.2 Hz, 1H, Harom), 7.56 (d, JHF = 7.8 Hz, 1H, Harom), 5.15 (pt, JHH = 1.8 Hz, 2H, α-
C5H4), 4.85 (pt, JHH = 1.8 Hz, 2H, β-C5H4), 4.65 (s, 5H, C5H5), 3.82 (m, 1H, CH cyclopropyl), 













































































3.33 (t, JHH = 4.2 Hz, 4H, C4H8N2), 2.81 (t, JHH = 7.2 Hz, 2H, CH2), 2.69 (t, JHH = 7.2 Hz, 2H, 
CH2), 2.63 (t, JHH = 4.2 Hz, 4H, C4H8N2), 1.30 (pq, JHH = 6.0 Hz, 2H, CH2 cyclopropyl), 1.18 
(pt, JHH = 6.0 Hz, 2H, CH2 cyclopropyl). 13C{1H} NMR (150 MHz, DMSO-d6):  = 200.4, 
176.4, 166.0, 153.1 (d,1JCF = 249.6 Hz), 148.1, 145.3 (d, 2JCF = 10.3 Hz), 139.3, 118.6, 111.0 
(d, 2JCF = 23.1 Hz), 106.8, 106.4, 84.0, 73.7, 72.0, 70.7, 55.0, 53.3, 52.4, 49.5, 36.0, 7.7. EI-
MS: m/z = 618 [M+H]+. FTIR (KBr ν [cm-1]): 3446 (COOH), 3091, 2908, 2838, 1730 (C=O), 
1672 (C=O), 1629 (C=O), 1612 (C=O), 1502, 1463, 1260. Anal. Calcd for C30H30N3O4FRu 
(%): C 58.43, H 4.90, N 6.81; Found: C 58.29, H 4.82, N 6.70.
6: 1H NMR (600 MHz, DMSO-d6):  = 15.20 (s, 1H, COOH), 8.65 (s, 1H, =C-H), 7.90 (d, 
JHF = 13.8 Hz, 1H, Harom), 7.55 (d, JHF = 6.0 Hz, 1H, Harom), 5.85 (s, 2H, α-C5H4), 5.22 (s, 2H, 
β-C5H4), 3.83 (s, 1H, CH cyclopropyl), 3.30 (4H of the C4H8N2 moiety are under the residual 
water signal), 2.87 (t, JHH = 7.2 Hz, 2H, CH2), 2.71 (t, JHH = 7.2 Hz, 2H, CH2), 2.64 (s, 4H, 
C4H8N2), 1.30 (d, JHH = 5.4 Hz, 2H, CH2 cyclopropyl), 1.18 (s, 2H, CH2 cyclopropyl). 
13C{1H} NMR (150 MHz, DMSO-d6):  = 223.8, 196.7, 176.5, 166.1, 156.5, 153.1 (d,1JCF = 
252.0 Hz), 148.0, 145.2 (d, 2JCF = 10.3 Hz), 139.2, 118.6, 111.0 (d, 2JCF = 23.1 Hz), 106.7, 
106.3, 92.2, 87.7, 85.2, 52.4, 52.3, 49.4, 36.2, 7.6. EI-MS: m/z = 590 [M+2H]+. FTIR (KBr ν 
[cm-1]): 3433 (COOH), 3065, 2951, 2905, 2845, 2020 (Mn-CO), 1925 (Mn-CO), 1725 (C=O), 
1675 (C=O), 1629 (C=O), 1497, 1467. Anal. Calcd for C28H25N3O7FMn (%): C 57.05, H 
4.27, N 7.13; Found: C 57.01, H 4.48, N 6.91.
X-ray structure analysis
Good quality single-crystals of 4 and 6 were selected for X-ray diffraction experiments at T = 
100(2) K. Diffraction data were collected on an Agilent Technologies SuperNova Dual 
Source diffractometer with CuKα radiation (λ = 1.54184 Å) using CrysAlis RED software.67 
The analytical numerical absorption correction using a multifaceted crystal model based on 
expressions derived by R.C. Clark & J.S. Reid68 implemented in SCALE3 ABSPACK scaling 
algorithm was applied for both compounds.67 The structural determination procedure was 
carried out using the SHELX package.69 The structures were solved with direct methods and 
then successive least-square refinement was carried out based on the full-matrix least-squares 
method on F2 using the SHELXL program.69 The H-atoms linked to O-atoms were located 
from the Fourier difference electron density map and refined with Uiso(H) = 1.5Ueq(O). 
Remaining H-atoms were positioned geometrically, with C–H equal to 0.93, 0.97 and 0.98 Å 
for the aromatic, methylene and methine H-atoms, respectively, and constrained to ride on 













































































their parent atoms with Uiso(H) = 1.2Ueq(C). In case of 6, a few distinct peaks on the 
difference Fourier map indicated the presence of a disordered solvent molecule. All attempts 
to model a disordered solvent used for crystallization failed. Therefore, the solvent 
contribution has been removed applying the appropriate MASK procedure in Olex2 
program.70 Calculated solvent accessible volume was approximately 174.9 Å3 occupied by 
52.6 electrons per unit cell. The cyclopropyl fragment in 6 was disordered over two positions 
with refined occupancy ratio of 0.62(2) : 0.38(2). All C−C bond lengths of disordered moiety 
were subject of SADI restraints. In case of the ferrocenyl 4, RIGU restraint was applied. All 
molecular interactions in the crystals were identified using PLATON program.71 The figures 
for this publication were prepared using Olex2 and Mercury programs.70,72
The CCDC 1952897 (4) and 1952898 (6) contains the supplementary crystallographic data for 





The in vitro antimicrobial activity of the six organometallic ciprofloxacin derivatives was 
evaluated using a set of reference Gram-negative bacteria strains (E. coli ATCC 25922, E. 
coli NCTC 8196, P. vulgaris ATCC 49990, K. pneumoniae ATCC 13883) and Gram-positive 
bacteria strains (S. aureus ATCC 6538, S. aureus ATCC 29213, S. epidermidis ATCC 
12228). In addition, two clinical isolates of methicillin-resistant S. aureus (MRSA) obtained 
from infected bones of patients hospitalized at the Oncological Hospital in Łódź (Poland), as 
well as a S. aureus ATCC 6538 mutant resistant to high concentrations of ciprofloxacin were 
also tested. All strains were kept frozen at −80 °C on Tryptic Soy Broth with 15% of glycerol 
until testing. The minimal inhibitory concentration (MIC) was defined as the lowest 
concentration of the compound preventing visible growth of the microorganism using the 
microdilution method according to EUCAST guidelines [ISO 20776-1 (2006)]. Each 
compound was pipetted into wells of 96-well microplates as a series of two-fold dilutions in 
Mueller-Hinton broth in the concentration range from 0.2 to 50 μM. For the most active 
compounds, further dilutions were made in order to determine their MIC values.  All 
compounds were dissolved in dimethylformamide (DMF)73 The final concentration of DMF 
in media was 1% which had no influence on the growth of the microorganisms. Then, bacteria 
were added at an inoculum of approximately 5 × 105 CFU/mL. The plates were incubated at 













































































37°C for 18 h and the optical density (OD600) was measured using SpectraMax i3 Multi-Mode 
Platform (Molecular Devices).
Minimal bactericidal concentration (MBC), defined as the lowest concentration of a 
compound that resulted in >99.9% reduction in CFU/mL of the initial inoculum, was 
determined following MIC evaluation by plating out the contents of the first well that showed 
no visible growth of bacteria, as well as the two next wells with higher concentrations of the 
compound onto Mueller-Hinton agar plates. Then, the plates were incubated at 37 °C for 18 h.
Ciprofloxacin hydrochloride (CIP, Sigma-Aldrich PHR-1044) was used as a reference 
antimicrobial agent for both MIC and MBC measurements. All evaluations were performed in 
triplicates.
Selection of S. aureus CIPR 
Staphylococcus aureus ATCC 6538 mutant resistant to high concentrations of ciprofloxacin 
(CIPR) was obtained in our laboratory through selection on agar plates with increasing 
concentrations of the antibiotic. Initially, an inoculum of 2 x 108 CFU/mL of the wild type S. 
aureus ATCC 6538 was plated on agar plates containing ciprofloxacin at the concentration of 
¼ MIC. After 24 h incubation, growing colonies were transferred to plates containing 
increasingly higher concentrations of ciprofloxacin of 1/2 MIC, MIC, 2 x MIC, 4 x MIC, etc., 
until the resulting mutants were resistant to 60 x MIC of CIP. The selected individual colonies 
of the obtained mutant were then transferred to the Mueller-Hinton broth medium 
supplemented with 10 x MIC of ciprofloxacin, incubated overnight and used for susceptibility 
testing. Several passages were performed in order to check the stability of phenotype.
Antibacterial activity in the presence of NAC
The antibacterial activity of compounds in the presence of the antioxidant N-acetyl-L-cysteine 
(NAC) was determined in the same way as described above, except that 5 μL of NAC was 
added to each well to give a final concentration of 10 mM/well. In addition, the influence of 
NAC itself on bacterial growth was also assessed. All evaluations were performed in 
triplicates. 
Antibacterial studies of stationary-phase E. coli and S. aureus 
High cell density stationary-phase cultures of E. coli ATCC 25922 and S. aureus ATCC 
29213 grown in Mueller-Hinton broth for 24 h were treated with 0.1 μM of 4, 5, 6 and 2 μM 
of 3, 6, respectively. After 24 h incubation, the number of CFU/mL was determined by 
seeding serial dilutions of cultures on agar plates. Ciprofloxacin hydrochloride was used as a 
control antimicrobial agent.  The results were presented as mean CFU/mL ± SEM from three 













































































independent experiments. Comparisons between tested compounds and untreated control were made 
using One-way ANOVA analysis of variance with Tukey’s multiple comparison post-test. 
Topoisomerases inhibition
The inhibitory activity of the six organometallic ciprofloxacin derivatives against E. coli DNA 
gyrase and S. aureus topoisomerase IV was evaluated using a gyrase supercoiling assay kit 
and a topoisomerase IV decatenation kit (Inspiralis, K0001 and SAD4001). The supercoiling 
assay was performed using a relaxed pBR322 plasmid (0.5 μg) as a substrate. The DNA was 
incubated with 1 U of gyrase in the provided supercoiling assay buffer in the presence of 50 
μM of test compounds. Reactions were carried out at 37 °C for 1 h and then terminated by the 
addition of an equal volume of 2 × STOP Buffer (40% sucrose, 100 mM Tris-Cl pH 7.5, 1 
mM EDTA, and 0.5 mg/mL bromophenol blue) and chloroform/isoamyl alcohol. Samples 
were vortexed, centrifuged and separated on a 0.8 % agarose gel in TAE buffer (40 mM Tris-
acetate, 2 mM EDTA) for 2 h at 70 V. After electrophoresis, gels were stained with ethidium 
bromide and visualized under UV light. The decatenation assay was performed using an 
interlinked kDNA substrate (0.5 μg) incubated with 1 U of topoisomerase IV in the provided 
decatenation assay buffer in the presence of 50 μM of the test compounds. Reactions were 
carried out at 37 °C and electrophoresis was performed under same conditions as described 
for the supercoiling assay. For two selected compounds (3 and 6), detailed analyzes were 
performed by using a concentration range of 5-50 μM. IC50 values (concentration that 
inhibited the activity of the enzymes by 50%) were determined based on densitometric 
evaluations of electrophoregrams using Quantity One software (BioRad).
Scanning Electron Microscopy
To evaluate the effect of the compounds 4-6, as well as CIP on bacterial cells, their 
morphology was studied by SEM as previously described.74 Briefly, compounds were added 
to bacterial cell cultures at a concentration equal to their MIC values and incubated for 12 h 
under shaking (37 ºC). Then, bacterial samples were washed with PBS (0.1 M), fixed in 
glutaraldehyde (2.5%) for 90 min, and dehydrated in ethanol solutions (30-100%) twice for 15 
min. Prior to SEM visualization, samples were coated with Pt (15 nm). SEM images were 
acquired using SEM Inspect F50 (10-15keV; FEI Co., LMA-INA, Spain).
Antitrypanoosmal activity evaluation
The trypanocidal activity of organometallic ciprofloxacin derivatives was determined with 
bloodstream forms of T. brucei 427/22175 using the resazurin vital dye method.76 For 
comparison, compounds were also tested for their cytotoxic effect on human leukemia HL-60 













































































cells. Cells were seeded in 96-well plates in a final volume of 200 μl of Baltz medium77 
supplemented with 16.7% bovine serum containing different concentrations of test 
compounds (10-4 to 10-9 M) and 0.9% DMSO. Wells containing medium and 0.9% DMSO 
served as controls. The initial densities were 1  104/ml trypanosomes and 5  104/ml HL-60 
cells. After 24 h incubation at 37 °C in a humidified atmosphere containing 5% CO2, 20 μl of 
a 0.5 mM resazurin solution prepared in sterile PBS was added and the cells were incubated 
for a further 48 h so that the total incubation time was 72 h. Then, the plates were read on a 
microplate reader using a test wavelength of 570 nm and a reference wavelength of 630 nm. 
GI50 values were calculated by linear interpolation using the method of Huber and Koella.78 
MIC values were determined microscopically.
Cell viability assay
The effect of the six organometallic ciprofloxacin derivatives on the viability of mammalian 
cells was determined with the MTT reduction assay. Murine fibroblasts L929 cells (ATTC 
®—CCL-1) and human tumor HeLa cells (ATTC ®—CCL-2™) were plated in 96-well 
microplates at a density of 1 × 104 cells/well according to international standard ISO 10993-
5:2009(E) (American National Standard 2009) in Dulbecco's Modified Eagle Medium 
(DMEM, Biowest) supplemented with 10% fetal bovine serum (FBS, Biowest), 100 U/mL of 
penicillin, and 100 μg/mL of streptomycin (Biowest). Cell cultures were incubated at 37 °C in 
a humidified atmosphere containing 5% CO2. After overnight incubation, growth medium was 
removed and 100 μL of fresh medium supplemented with two-fold dilutions of test 
compounds in a concentration range of 0.4–50 μM were added. All test compounds were 
dissolved in DMF, which final concentration in medium did not exceed 1%. Thus,  DMF at 
the concentration of 1%, served as a negative control, however, concentrations of DMF up to 
2% were found not harmful to the tested cell lines (data not shown). After 24 h incubation, the 
medium was removed and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT, Sigma-Aldrich M-5655) at a concentration of 50 μg/well was added. Plates were 
incubated for the next 2 h at 37 °C, 5% CO2. Then, formazan crystals were solubilized in 150 
μL DMSO and quantified by spectrophotometric measurement at 550 nm by using 
SpectraMax i3 Multi-Mode Platform (Molecular Devices). The results of the experiments 
were shown as mean arithmetic values from 3 repeats in each of two independent experiments 
and the percentage of viability inhibition was calculated in comparison with the untreated 
controls. GI50 values (drug concentration that inhibits cell viability by 50%) were calculated 
with the Prism GraphPad 7 software using nonlinear regression. Additionally, the GI50/MIC 













































































ratio was determined for each of the compounds in order to evaluate their selective activity 
towards bacteria in comparison to mammalian cells.
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Organometallic ciprofloxacin conjugates were synthesized and showed two mechanisms of 
antimicrobial activity. The first mechanism involves inhibition of type IIA topoisomerases 
and the second ROS generation in bacterial cells.
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